SCHEMBL6047669

SCHEMBL6047669

CCCC(O)Cc1ccccc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.39
CTBP2 P56545 1/20 0.39
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
SHBG P04278 1/20 0.37
DNM1 Q05193 1/20 0.37
NR3C1 P04150 1/20 0.37
PGR P06401 1/20 0.37
NR3C2 P08235 1/20 0.37
KMT2A Q03164 1/20 0.37
SLC6A2 P23975 3/20 0.36
SLC6A4 P31645 3/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
AOC3 Q16853 1/20 0.36
SLC6A3 Q01959 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
KCNH2 Q12809 1/20 0.36
HPGD P15428 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14402393 1.00 TAAR1 (0.39) TAAR1CTBP2PPARGPPARASHBG
SCHEMBL13849916 1.00 TAAR1 (0.39) TAAR1CTBP2PPARGPPARASHBG
SCHEMBL6204279 0.85 KDM4E (0.40) TAAR1CTBP2PPARGPPARADNM1
SCHEMBL6424581 0.84 TAAR1 (0.42) TAAR1CTBP2PPARGPPARASHBG
SCHEMBL8349103 0.84 TAAR1 (0.42) TAAR1CTBP2PPARGPPARASHBG
SCHEMBL3652083 0.83 TAAR1 (0.47) TAAR1CTBP2SHBGDNM1KMT2A
SCHEMBL15319376 0.83 TAAR1 (0.42) TAAR1PPARGPPARADNM1KMT2A
SCHEMBL10643876 0.83 PPARG (0.40) TAAR1CTBP2PPARGPPARADNM1
SCHEMBL15178121 0.82 TAS1R3 (0.42) PPARGPPARASLC6A2SLC6A4AOC3
SCHEMBL15178323 0.81 HSPA5 (0.45) TAAR1SLC6A2SLC6A4SLC6A3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130245132-A1 PROCESS FOR PREPARING 4-CYCLOHEXYL-2-METHYL-2-BUTANOL BASF SE (DE) 2013-09-19 US claimed
WO-2017146128-A1 IMIDAZOLYLAMIDE DERIVATIVE 大日本住友製薬株式会社 2017-08-31 WO disclosed
EP-1847533-B1 SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2013-08-14 EP disclosed
CN-101484187-A Composition comprising dissociated glucocorticoid receptor agonist and immunosuppressant for treating dry eye BAUCH & LOMB INC (US) 2009-07-15 CN disclosed
US-7531533-B2 6-Membered heterocyclic compound and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-05-12 US disclosed
EP-1847533-A1 SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF Asahi Kasei Pharma Corporation (JP) 2007-10-24 EP disclosed
US-20070060590-A1 6-Membered heterocyclic compound and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2007-03-15 US disclosed
US-7119123-B2 Antimicrobially active 4-methyl-4-aryl-2-pentanols, their preparation and use SYMRISE GMBH & CO. KG (DE) 2006-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060590-A1 6-Membered heterocyclic compound and use thereof WNT1, CYP11B2, CYP11B1 TAAR1 4612/4885CTBP2 2100/4885PPARG 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.